COMMUNIQUÉS West-GlobeNewswire

Quotient Limited Reports Senior Note Issuance and Warrant Cash Inflows and updates on MosaiQ Development and First Quarter Fiscal 2019 Financial Results
06/08/2018
$48.8 million of proceeds from warrant exercises received through July 31 $36 million of additional senior notes issued and funded in June Initial SDS microarray verification and validation started Record reagent [...]
Gemphire Provides Update On Development of Gemcabene
06/08/2018
FDA requests the Company provide additional data regarding the partial clinical hold Company continues Phase 2 development of gemcabene for NAFLD/NASH Company amends loan agreement with SVB to provide additional [...]
Dermira Reports Second Quarter 2018 Financial Results and Provides Corporate Update
06/08/2018
- QBREXZA™ (glycopyrronium) cloth for the treatment of primary axillary hyperhidrosis approved in June 2018 - QBREXZA expected to be available nationwide in pharmacies beginning in October 2018 - Lebrikizumab Phase 2b [...]
Iovance Biotherapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
06/08/2018
- Company to Host Conference Call at 4:30pm ET Today - SAN CARLOS, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies [...]
Achaogen Reports Second Quarter 2018 Financial Results and Provides Corporate Update
06/08/2018
-- ZEMDRI (plazomicin) , approved in the U.S. for the treatment of adults with complicated urinary tract infections -- -- Launch of ZEMDRI underway; reached more than three quarters of high priority accounts in first [...]
Gemphire Announces Amended and Restated Gemcabene License Agreement with Pfizer Inc.
06/08/2018
LIVONIA, Mich., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, [...]
BioCryst Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock
06/08/2018
RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the completion of an underwritten public offering of 10,454,546 shares of its common stock, [...]
Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101
06/08/2018
Reinforces both Allergan’s and Editas’ continued commitment to developing innovative treatments for unmet needs in eye care EDIT-101 is Editas Medicine’s experimental CRISPR genome editing medicine for the treatment of [...]
Dynavax Reports Second Quarter 2018 Financial Results
06/08/2018
HEPLISAV-B® Launch Progressing as Planned with Key Customer Successes Three abstracts accepted for presentation at European Society for Medical Oncology (ESMO) 2018 Annual Meeting Conference Call to be held at 4:30pm ET [...]
Devonian Health Group provides an update on its previously announced private placement
06/08/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN THE UNITED STATES. QUEBEC CITY, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Devonian Health Group Inc. ( “Devonian” or the “Corporation” ) (TSX VENTURE:GSD), a [...]
Groupe Santé Devonian fournit une mise à jour sur son placement privé préalablement annoncé
06/08/2018
NE PAS DISTRIBUER AUX AGENCES DE PRESSE AMÉRICAINES NI DIFFUSER AUX ÉTATS-UNIS QUÉBEC, 06 août 2018 (GLOBE NEWSWIRE) -- Groupe Santé Devonian Inc. ( « Devonian » ou la « Société » ) (TSX CROISSANCE:GSD), une société [...]
ContraVir Pharmaceuticals Provides an Update to Corporate Objectives
06/08/2018
EDISON, N.J., Aug. 06, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of [...]
Nohla Therapeutics Receives FDA Fast Track Designation for Dilanubicel for Allogeneic Cord Blood Transplant Patients
06/08/2018
SEATTLE, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases, today announced that [...]
Essilor: Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2018
06/08/2018
Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2018 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
Essilor : Nombre total de droits de vote et d'actions composant le capital social au 31 juillet 2018
06/08/2018
Nombre total de droits de vote et d'actions composant le capital social au 31 juillet 2018 (Article L.233-8 II du Code de Commerce et les articles 221-1 et 223-16 du Règlement Général de l'AMF) Charenton-le-Pont, France [...]
Sanofi: Disclosure of trading in own shares
06/08/2018
Attachment Reporting EN.pdf
Sanofi : Déclaration des transactions sur actions propres
06/08/2018
Pièce jointe Reporting FR.pdf
VALNEVA : Déclaration d'actions et de droits de vote - JUILLET 2018
06/08/2018
Dénomination sociale : VALNEVA Adresse du siège social : 6 rue Alain Bombard, 44800 Saint-Herblain Marché réglementé Euronext Paris de Nyse Euronext - Compartiment B Date de la déclaration : Déclaration du 6 août 2018 [...]
ARM Foundation for Cell and Gene Medicine Releases Health Economic Impact Landscape Analysis Led by IQVIA
06/08/2018
Washington, D.C., Aug. 06, 2018 (GLOBE NEWSWIRE) -- The ARM Foundation for Cell and Gene Medicine (ARM Foundation) today released its first-of-its-kind Health Economic Impact Landscape Analysis of regenerative medicine [...]

Pages